6 not yet recruiting. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Not yet recruiting 6 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine - Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 9 | 2026-07-01 | 2026-06-09 |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis CAR-T Therapy - ANCA Associated Vasculitis (AAV) | Phase 1 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2025-07-01 | 2025-06-24 |
| UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Changzhou No.2 People's Hospital | 18 | 2025-05-01 | 2025-05-18 |
| Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy - ANCA-IgG-positive ANCA Associated Vasculitis | Phase 1 / Phase 2 | Not yet recruiting | David Simon | 8 | 2025-01-01 | 2024-09-19 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (5) · Lupus Erythematosus, Systemic (3) · Myositis (3) · Scleroderma, Diffuse (2) · Scleroderma, Systemic (2) · Sjogren's Syndrome (2) · Anemia, Hemolytic, Autoimmune (1) · Antiphospholipid Syndrome (1) · HIV Seropositivity (1) · Immunoglobulin G4-Related Disease (1) · Myasthenia Gravis (1) · Recurrence (1)
Cardiovascular Diseases (6) · Immune System Diseases (6) · Vascular Diseases (6) · Autoimmune Diseases (5) · Skin Diseases (5) · Skin Diseases, Vascular (5) · Skin and Connective Tissue Diseases (5) · Systemic Vasculitis (5) · Connective Tissue Diseases (4) · Muscular Diseases (3) · Musculoskeletal Diseases (3) · Nervous System Diseases (3) · Neuromuscular Diseases (3) · Arthritis (2)
Cyclophosphamide (1) · Immunotherapy, Adoptive (1) · fludarabine (1)
Changzhou No.2 People's Hospital (1) · Children's Hospital of Fudan University (1) · David Simon (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Peking University Third Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (3)
PMID 12631091, PMID 18528326, PMID 2161532, PMID 21859691, PMID 32291416, PMID 32855422, PMID 34347960, PMID 34501224, PMID 36109639, PMID 36927642, PMID 37748491, PMID 38182404, PMID 38381673